BBIO — BridgeBio Pharma Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Data provided bySource: Twelve DataPrice data
- Price
- $76.80
- YTD price return
- +0.41%
- YTD total return
- +0.41%
- Market cap
- 15B
- Enterprise value
- 16.1B
- Shares outstanding
- 194.8M
- 52W low
- $62.50
- 52W high
- $93.42
- From 52W high
- -17.79%
- From 52W low
- +22.88%
- 52W range
- 46%$62.50–$93.42
- Beta
- 0.98
Volume
- Rel volume
- 1.01×
- 30D volume
- 2.8M
- 30D $ vol
- 200M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- −$146K
- Insider net 3M
- −$837K
- Insider net 1Y
- −$76.5M
Form 4 transactions by trade date, as filed; latest on file 2026-10-30.
Fundamentals
- Sales (ttm)
- 945.5M
- Sales/share
- $4.85
- EPS (ttm)
- -$2.90
- FCF (ttm)
- -369.8M
- FCF/share
- -$1.90
- Book value/share
- -$8.53
- Net margin
- -59.84%
- ROA
- -26.17%
- Current ratio
- 2.09
Growth (CAGR, ttm) · 10Y
- Sales
- +167.45%+364.45%+75.42%n/a
- Shares
- +1.09%+3.84%+5.77%n/a
Per-share growth (CAGR, ttm) · 10Y
- Sales/share
- +164.57%+347.26%+65.85%n/a
- Price
- +14.81%+37.95%+10.75%n/a
- Total return
- +14.81%+37.95%+10.75%n/a
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- -26.5×
- Fwd P/E
- -283.0×
- P/S (ttm)
- 15.8×
- P/B (mrq)
- -9.0×
- EV/Sales (ttm)
- 17.0×
- FCF yield (ttm)
- -2.47%
- Buyback yield (realized, 1y)
- -1.09%
- Shareholder yield (realized, 1y)
- -1.09%
- Buyback yield (cash, ttm)
- 1.69%
- Shareholder yield (cash, ttm)
- 1.69%
Vs own 10Y history
- P/S
- 7th
Bar = where today’s multiple sits in BBIO’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-17#
Data provided bySource: Twelve DataFundamentals#
Operating income
5Y n/m5Y n/mYoY n/mEPS (diluted)
5Y n/m5Y n/mYoY n/mFree cash flow
5Y n/m5Y n/mYoY n/mTTM: operating cash flow −$369M, capex −$835K
Q3 2026: operating cash flow −$44.2M, capex −$290K
Shares (diluted)
5Y +62.3%5Y +62.3%YoY +2.2%Net income
5Y n/m5Y n/mYoY n/mAbout BridgeBio Pharma#
Data provided bySource: Twelve DataBridgeBio Pharma Inc. is a commercial-stage biopharmaceutical company focused on developing medicines for genetic conditions. BridgeBio Pharma Inc. discovers, develops, tests, and delivers therapies aimed at patients with rare and inherited diseases, with programs spanning cardiology, endocrinology, muscle disease, gene therapy, and selected oncology. The company’s current portfolio includes approved medicines such as Attruby for transthyretin amyloid cardiomyopathy and Nulibry for a rare metabolic disorder, alongside a pipeline of investigational treatments for additional genetic disorders. BridgeBio Pharma Inc. works with academic and industry partners to advance precision medicines and bring targeted treatment options to underserved patient groups. Headquartered in Palo Alto, California, BridgeBio Pharma Inc. plays a significant role in the genetic-disease biopharmaceutical market through its mix of commercial products and late-stage development programs.
Palo Alto, CA·999 employees·Biotechnology·bridgebio.com·As of Oct 28, 2026
Recent filings#
- Oct 29Earnings · Earnings release — EPS −$0.42 vs −$0.60 est. (+30.0%); revenue $353.2M (+193% y/y) 6.0%
- Oct 138-K · BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia
- Aug 318-K · BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
- Aug 178-K · BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder
- Aug 10Earnings · Earnings release — EPS −$0.78 vs −$0.64 est. (−21.9%); revenue $243.7M (+120% y/y) 1.1%
ETFs holding BBIO#
22 of the 193 ETFs ChartRow carries live hold BBIO. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| XBI | SPDR S&P Biotech ETF | 1.0% |
| IBB | iShares Biotechnology ETF | 1.0% |
| VBK | Vanguard Small-Cap Growth ETF | 0.4% |
| IWP | iShares Russell Mid-Cap Growth ETF | 0.3% |
| VB | Vanguard Small-Cap ETF | 0.2% |
| VHT | Vanguard Health Care ETF | 0.2% |
| VXF | Vanguard Extended Market ETF | 0.2% |
| IWR | iShares Russell Midcap ETF | 0.1% |
Related Healthcare#
Data provided bySource: Twelve Data| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +12.61% | -1.13% |
| JNJ | Johnson & Johnson | +9.05% | -1.36% |
| ABBV | AbbVie Inc. | +2.59% | -0.59% |
| MRK | Merck & Co. Inc. | -1.77% | -0.75% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | -2.93% | -5.42% |
| NVS | Novartis AG | +5.65% | -0.67% |
| TMO | Thermo Fisher Scientific Inc. | -0.47% | -0.66% |
| AMGN | Amgen Inc. | +5.88% | -0.95% |
